BRIEF-Valeant Pharmaceuticals Q1 adjusted non-gaap EPS $1.27

Tue Jun 7, 2016 6:11am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

June 7 (Reuters) - Valeant Pharmaceuticals International Inc :

* Updating its full year 2016 guidance

* FY adjusted ebitda (non-gaap) is expected to be in range of $4.80 - $4.95 billion

* FY 2016 earnings per share view $8.46, revenue view $10.86 billion -- Thomson Reuters I/B/E/S

* "We have made progress toward stabilizing organization over past few months"

* While we recognize that we did not meet timeline for filing Q1 results, with filing expected this week, we will be current in our financial reporting

* "Expect to file our financial results in a timely manner going forward"

* "There are some challenges to work through in certain business operations in 2016, such as our u.s. Dermatology unit"

* Full year 2016 total revenue guidance updated from previous guidance of $11.0 - $11.2 billion   Continued...